



**ONCOPOLICY FORUM 2011**

**- PROGRAMME -**

**Theme: Health Inequalities**

**OVERVIEW**

**Track Chair: Michael Baumann (DE)**

**Track Chair: David Kerr (UK)**

**SCHEDULE OVERVIEW**

**Monday 26 September 2011**

Time	Duration	Title
08.00 – 09.00	1h	Special Session
09.00 – 11.00	2h	Session 1
12.45 – 13.05	20 mins	Richard Sullivan, Kings Health Partners Integrated Cancer Centre and Martin Seychell, Deputy Director for Consumers and Health, European Commission, Presidential Session (Hall A1)
13.15 – 14.15	1h	Session 2
14.45 – 16.45	2h	Session 3
17.00 – 18.00	1h	Session 4

**Tuesday 27 September 2011**

Time	Duration	Title
09.00 – 09.20	20min	José Mariano Gago, former Portuguese Minister for Science, Technology and Higher Education, Presidential Session (Hall A1)
09.45 – 11.30	1h45	Session 5
11.30 – 12.30	1h	Session 6

**SPECIAL SESSION: Hall T6**  
**European Public Health, Research and Innovation Funding Opportunities**  
**Monday, 26 September 2011 from 08.00 – 09.00 (1 hour)**

Title	Speaker	Time
Chair: Julio Celis (ECCO Policy Committee)		
■ Introduction - Julio Celis		08.00
■ Public Health Funding Opportunities (DG Sanco) – Stefan Schreck		08.05
■ Research Funding Opportunities (DG Research) – Jan Willem van de Loo		08.15
■ Research Funding Opportunities (ERC) – José Labastida		08.25
■ Innovative Medicines Initiative Funding Opportunities (IMI)– Fatiha Sadallah		08.35
Q&A from the floor – 08.45 (10')		
Concluding remarks	Julio Celis	08.55

**SESSION 1: Hall T1**  
**BOOSTING CANCER CLINICAL TRIALS IN EUROPE**  
**Monday, 26 September 2011 from 09.00 – 11.00 (2 hours)**

Title	Speaker	Time
Status Quo of European Clinical Trials	Michael Baumann (ECCO President)	09.00
Bureaucracy in cancer clinical trials across Europe: stop complaining and start acting	Françoise Meunier (EORTC)	09.10
Pivotal cancer clinical trials: the importance of having European governments involved	Martine Piccart (BIG)	09.25
PANEL DISCUSSION – Chair: Ingrid Klingmann (EFGCP) – 09.40 (5' each responding to presentations and personal viewpoints from 09.45)		
■ Martin Seychell (DG Health and Consumers)		
■ Jacek Jassem (European Academy of Cancer Sciences)		
■ Otmar Wiestler (German Consortium for Translational Cancer Research)		
■ Roger Wilson (Sarcoma UK)		
■ Elena Colajori (Europabio)		
General Discussion - Q&A from the floor – 10.15 (35')		
Concluding remarks	Michael Baumann	10.50

**SESSION 2: Hall T1**  
**INEQUALITIES IN ACCESS TO CANCER DRUGS IN EUROPE**  
**Monday, 26 September 2011 from 13.15 – 14.15 (1 hour)**

Title	Speaker	Time
Overview of topic	Richard Sullivan (Kings Health Partners Integrated Cancer Centre)	13.15
Chair: Richard Sullivan		
(5' each responding to presentation and personal viewpoints from 13.25)		
<ul style="list-style-type: none"> <li>■ Måns Rosén (SBU - Swedish Council on Technology Assessment in Health Care)</li> <li>■ Francesco Pignatti (EMA - European Medicines Agency)</li> <li>■ Kathy Oliver (IBTA - International Brain Tumour Alliance)</li> <li>■ Paolo Casali (ESMO – European Society for Medical Oncology)</li> <li>■ Bengt Jönsson (Stockholm School of Economics)</li> <li>■ Nils Wilking (University of Lund)</li> </ul>		
General Discussion - Q&A from the floor – 13.50 (20')		
Conclusions	Richard Sullivan	14.10

**SESSION 3: Hall T1**  
**PROMOTING INNOVATIVE CANCER RESEARCH IN EUROPE**  
**Monday, 26 September 2011 from 14.45 – 16.45 (2 hours)**

Title	Speaker	Time
Introduction and state-of play	Julio Celis (ECCO Policy Committee)	14.45
Inequalities in research and the importance of sustainability of EU projects	Peter Lange (former Director General German Ministry of Education and Research (BMBF))	14.55
Moderator: Alexander M.M. Eggermont (European Academy of Cancer Sciences) – 15.10		
(10' each on working together in cutting-edge examples of collaboration on different levels addressing inequalities and linking this with sustainability from 15.15):		
<ul style="list-style-type: none"> <li>■ Kurt Zatloukal (BBMRI)</li> <li>■ Ruedi Aebersold (Institute of Molecular Systems Biology, Switzerland)</li> <li>■ Hans-Olov Adami (Clinical Science, European Academy of Cancer Sciences)</li> <li>■ Otmar Wiestler (German Consortium for Translational Cancer Research)</li> <li>■ Maria Ferrantini (Transcan)</li> </ul>		
General Discussion - Q&A from the floor – 16.05 (35')		

**SESSION 4: Hall T1**  
**ADDRESSING INEQUALITIES THROUGH THE EUROPEAN PARTNERSHIP FOR**  
**ACTION AGAINST CANCER**

**Monday, 26 September 2011 from 17.00 – 18.00 (1 hour)**

Title	Speaker	Time
Chair: Peter Naredi (ESSO)		
■ Overview of the Session - Peter Naredi		17.00
■ Introduction to EPAAC – Sandra Rados (National Institute of Public Health, Slovenia)		17.05
■ How the Partnership addresses inequalities - Julio Celis (ECCO)		17.15
■ Marisa Matias (European Parliament)		17.25
■ Stefan Schreck (DG Health and Consumers, European Commission)		17.35
General Discussion - Q&A from the floor – 17.45 (10')		
Concluding remarks	Peter Naredi	17.55

**SESSION 5: Hall T1**  
**INEQUALITIES IN QUALITY CANCER CARE**

**Tuesday 27 September 2011 from 09.45 – 11.30 (1 hour, 45 mins)**

Title	Speaker	Time
Introduction (overview of session, including guidelines, recognition of medical qualification, reference to data, multidisciplinary and multiprofessionalism)	David Kerr (ESMO)	09.45
Service delivery challenges and solutions in Europe	Kathy Redmond (Cancer World)	09.55
PANEL DISCUSSION – Chair: Nick Fahy (Nick Fahy Consulting) – 10.10 (5' each responding to presentations and personal viewpoints from 10.15)		
■ Marisa Matias (European Parliament)		
■ Regine Hagmann (Head of the German Cancer Information Service, German Cancer Research Center (DKFZ))		
■ Anna Kamińska (Ministry of Health, Poland)		
■ Stella Kyriakides (ECCO PAC Chair)		
■ Cornelius van de Velde (ECCO President-Elect)		
■ Sara Faithfull (EONS – European Oncology Nursing Society)		
■ Nicole Denjoy (COCIR - European Coordination Committee of the European Radiological, Electromedical and Healthcare IT Industry)		

General Discussion - Q&A from the floor – 10.50 (35')

Concluding remarks

David Kerr

11.25

**SESSION 6: Hall T1  
NATIONAL CANCER PLANS**

**Tuesday 27 September 2011 from 11.30 – 12.30 (1 hour)**

Title	Speaker	Time
Introductory overview of NCCP situation in EU and EEA	José Martin-Moreno (WHO)	11.30
PANEL DISCUSSION: Is there a role for the EU in NCCPs?		
Chair: Josep Figueras (European Observatory) – 11.40		
(5' each responding to question from 11.45)		
<ul style="list-style-type: none"><li>■ David Khayat, French National Cancer Plan (Hôpital de la Salpêtrière France) (pro question)</li><li>■ Anna Kaminska (Polish Ministry of Health)</li><li>■ Harri Vertio, Finnish Cancer Strategy (alternative solutions to NCCPs)</li><li>■ Tit Albreht, European Partnership for Action Against Cancer (WP10 leader on NCCPs)</li><li>■ Michel Coleman (London School of Hygiene and Tropical Medicine)</li></ul>		
General Discussion - Q&A from the floor – 12.10 (15')		
Concluding remarks	José Martin-Moreno	12.25